Market Trends of North America Anesthesia Drugs Industry
This section covers the major market trends shaping the North America Anesthetic Drugs Market according to our research experts:
Inhalation Segment is Expected to Grow Over the Forecast Period
Sevoflurane is used to induce and maintain general anesthesia and sedation. The most common inhalation anesthetics are sevoflurane, desflurane, and nitrous oxide. Sevoflurane is the most common due to its rapid onset of action and quick patient recovery. The sevoflurane segment is expected to witness growth in the market owing to the increase in the adoption of inhalation anesthetics, surge in healthcare expenditure, and rise in product launches. For instance, according to the data updated by CIHI in November 2022, total health spending in Canada was expected to reach USD 331 billion in 2022, or USD 8,563 per Canadian. It was anticipated that health expenditures would represent 12.2% of Canada's gross domestic product (GDP) in 2022, following a high of 13.8% in 2020. Thus, this increasing healthcare expenditure in the country is predicted to impact the availability of inhalation anesthesia drugs, driving segment growth during the analysis period.
Sevoflurane is an ether inhalation anesthetic agent with low pungency, a non-irritant odor, and a low blood and gas partition coefficient. According to the data updated by the NCBI in September 2022, sevoflurane is the most widely used inhalation anesthetic, owing to its therapeutic advantages and low cost. Furthermore, in June 2022, Ciusss de L'Est de l'Île de Montréal sponsored a clinical study to compare the analgesic properties of two commonly used agents for induction and maintenance of the hypnotic component of anesthesia: propofol versus sevoflurane. Thus, the demand for sevoflurane is increasing. Hence, the studied segment is expected to witness growth during the forecast period due to the abovementioned factors.
Therefore, due to the increase in healthcare expenditures and the rise in research activities involving sevoflurane in North America, the segment studied is expected to witness growth over the forecast period.
United States is Anticipated to Witness Growth Over the Forecast Period
The United States is expected to hold a major share of the overall market throughout the forecast period. The major factors attributing to the growth are the growing prevalence of multiple chronic diseases, the increasing number of surgeries, and rising product developments by the major market players.
The United States is witnessing a rise in chronic diseases among the target population. And most of them require surgery for treatment. For instance, as per the American Cancer Society, the estimated number of people affected by cancer in 2022 was 1.9 million in the United States. Similarly, as stated by the American Heart Association 2021 journal, it is estimated that by the year 2035, more than 130 million adults in the United States will have some type of heart disease.
In addition, as per the annual report released by the AJRR in November 2021, around 2,244,587 primary and revision hip and knee arthroplasty procedures were performed between 2012 and 2020. Primary knee (54.5%) and primary hip (38.5%) procedures made up most of the orthopedic surgeries in the country during the period. In addition, as per the AJRR this year, there were around 105,743 hip arthroplasty procedures for femoral neck fractures in the United States in the base year. This shows a high number of the population requires orthopedic surgery, which is expected to increase the application of anesthesia drugs. Thus, the high burden of various diseases creates opportunities for the application and development of anesthesia drugs and is expected to fuel the market studied. Hence, the market is expected to witness high growth over the forecast period in the United States.
